HARP
- Harpoon Therapeutics, Inc.
()
Overview
Company Summary
Harpoon Therapeutics, Inc. (HARP) is a biotechnology company focused on developing novel immunotherapies to help treat cancer. The company utilizes a unique approach called T cell engagers, which are designed to improve the body's natural immune response to specifically target and eliminate cancer cells.
Harpoon's T cell engager platform consists of small proteins that can bind to both T cells (a type of immune cell) and tumor cells simultaneously. By doing so, these proteins activate and redirect the T cells to specifically recognize and destroy cancer cells. This approach enhances the immune system's ability to fight cancer by leveraging its own defense mechanisms.
The company's lead product candidate, known as HPN424, targets prostate-specific membrane antigen (PSMA) which is expressed in certain types of prostate cancer. Harpoon is also developing other product candidates targeting additional tumor types and antigens.
Harpoon Therapeutics combines cutting-edge biological research, protein engineering, and immunotherapy expertise to develop therapies that have the potential to provide more effective and targeted treatment options for cancer patients. By harnessing the power of the immune system, Harpoon aims to revolutionize cancer treatment and improve outcomes for patients.